21:09 , May 31, 2017 |  BC Extra  |  Clinical News

Scripps researchers synthesize potent vancomycin analog

Researchers at The Scripps Research Institute showed that multiple structural modifications to vancomycin made the antibiotic 25,000 times more potent than the parent compound and helped overcome the molecular basis of antibiotic resistance. Vancomycin binds...
21:54 , Feb 9, 2017 |  BC Week In Review  |  Company News

Vancocin vancomycin news

In a federal lawsuit, the U.S. Federal Trade Commission alleged that the Shire ViroPharma Inc. subsidiary of Shire abused the Citizen's Petition process and violated antitrust laws to delay generic competition for antibiotic Vancocin vancomycin....
00:51 , Feb 8, 2017 |  BC Extra  |  Company News

FTC suit alleges Shire abused FDA process

In a federal lawsuit , the U.S. Federal Trade Commission alleged that the Shire ViroPharma Inc. subsidiary of Shire plc (LSE:SHP; NASDAQ:SHPG) abused the Citizen's Petition process and violated antitrust laws to delay generic competition...
21:04 , Nov 11, 2016 |  BC Week In Review  |  Company News

Eli Lilly, Eddingpharm deal

Eli Lilly granted Eddingpharm exclusive rights to promote and distribute antibiotics Ceclor cefaclor and Vancocin vancomycin in mainland China, effective Jan. 1, 2017. Lilly said the deal will enable it to focus resources on its...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

Dalvance dalbavancin: Phase III data

Next quarter, Actavis plans to submit an sNDA to FDA for the single dose regimen of IV Dalvance. The 2-dose regimen of IV Dalvance is approved to treat ABSSSIs caused by susceptible Gram-positive bacteria, including...
08:00 , Feb 26, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: D-alanyl-D-alanine

Infectious disease INDICATION: Bacterial infection In vitro studies have identified vancomycin analogs with site-specific lipidation that could be useful for treating antibiotic-resistant Gram-positive bacterial infections. The glycopeptide antibiotic vancomycin is a cell wall synthesis inhibitor...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Clinical News

Dalbavancin: SPA received

Durata said it received an SPA from FDA for a Phase III trial to compare a single dose of 1,500 mg IV Dalvance plus a single dose of IV azithromycin vs. linezolid plus azithromycin in...
07:00 , May 5, 2014 |  BC Week In Review  |  Clinical News

Dalvance dalbavancin: Phase IIIb started

Durata began a double-blind, international Phase IIIb trial to compare a single 1,500 mg dose of IV Dalvance vs. 1,000 mg IV Dalvance given on day 1 followed by a 500 mg dose on day...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Clinical News

Dalbavancin: Phase III data

Durata previously reported that dalbavancin met both the FDA- and EMA-defined primary endpoints in the Phase III DISCOVER 1 trial in the indication (see BioCentury, Dec. 17, 2012 & Jan. 21, 2013). Durata, which has...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

Dalbavancin: Additional Phase III data

In a subgroup of patients with methicillin-resistant Staphylococcus aureus (MRSA), dalbavancin led to an early response defined as cessation of spread of the erythema of the lesion and resolution of fever at 48-72 hours after...